# Shravin Bharti Mittal

> Shravin Bharti Mittal is a Series B investor at Unbound (London) backing Health Care and FinTech. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Unbound](https://shizune.co/investors/profile/unbound-bdd5)
- Location: London, United Kingdom
- Total investments: 19
- Last investment: Jun 2025
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/shravin-bharti-mittal-b5561843/

Shravin Bharti Mittal is a Series B investor at Unbound in London focused on Health Care and FinTech. Shravin is the Founder of Unbound and a Director of Bharti Global Ltd (Bharti family office). Unbound is a globally focused long term technology investment arm that aims to build and back technology companies. Select investments include Databricks, mPharma and FreightHub. Bharti Global has numerous investments in Telecommunications, Technology,Energy and Hospitality. Portfolio companies: Airtel, One Web, Delonex Energy, TriTon, mPharma, Hike and Hoxton Hotels. Previously, Shravin was an Investor at Softbank (2016-2017). Prior to that, Shravin was an Assistant Director at Better Capital (2014-2015), a Private Equity firm in London. Between 2010 to 2012 Shravin was the MD at Airtel in Africa and India. Prior to that he worked with J.P.Morgan in Investment Banking Covering TMT. Shravin has an MBA from Harvard Business School (Class 2014) and founded Airtel Rising Stars (a youth football initiative in Africa and India).

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $4M–$5M |
| Series A | $6.6M–$19M |
| Series B | $9.7M–$29M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 16% |
| FinTech | 2 | 11% |
| Fitness | 2 | 11% |
| Wellness | 2 | 11% |
| Cryptocurrency | 2 | 11% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 26% |
| Seed | 3 | 16% |
| Series A | 3 | 16% |
| Series D | 2 | 11% |
| Series C | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 2 | 11% |
| United Kingdom | 2 | 11% |
| Ghana | 1 | 5% |
| Germany | 1 | 5% |
| Hong Kong | 1 | 5% |

7 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Syfe | Syfe is an investment and saving platform empowering people to build their wealth. Syfe offers fully managed portfolios, cash management solutions, and self-directed offerings through its unique neo-brokerage, making it the region’s only all-in-one wealth management platform. Syfe is fully licensed and operational for fund management, financialadvisory, and brokerage in Singapore, Hong Kong & Australia. The company has raised US$ 52.4m to date from prominent backers such as Valar Ventures (Transferwise, N26, Qonto), Unbound Capital (Forto, Cars24), and Partners from DST (Robinhood, Revolut, Brex, Coinbase). | $53M | Series C | Jun 05, 2025 |  |
| OpenOrigins | OpenOrigins is a software development company that offers tools for cryptography, trusted execution, and distributed systems. | $4.5M | Seed | Oct 31, 2024 |  |
| Syfe | Syfe is an investment and saving platform empowering people to build their wealth. Syfe offers fully managed portfolios, cash management solutions, and self-directed offerings through its unique neo-brokerage, making it the region’s only all-in-one wealth management platform. Syfe is fully licensed and operational for fund management, financialadvisory, and brokerage in Singapore, Hong Kong & Australia. The company has raised US$ 52.4m to date from prominent backers such as Valar Ventures (Transferwise, N26, Qonto), Unbound Capital (Forto, Cars24), and Partners from DST (Robinhood, Revolut, Brex, Coinbase). | $27M | Series C | Aug 13, 2024 |  |
| Bioniq | Bioniq is a health-tech company that provides personalized supplement formulas based on individual blood test results and health questionnaires. The company has developed a patented algorithm and database of over 6 million biochemical data points to create custom-made supplements containing up to 120 different nutrients in precise quantities foreach customer's unique nutritional requirements. | $15M | Series B | Jul 16, 2024 |  |
| Ecolibrium | The era of Climate change, not only presents the gravest challenge to Humankind, but also the biggest opportunity in this century to establish a more sustainable ecosystem.Global warming and energy crisis are two significant challenges facing the world today. Not only are they inter-linked, but their negative impact is accelerating as you readthis. The choice we have is clear: develop clean and smart energy infrastructure or ignore the dire consequences that will come with an unimaginable cost.An even bigger problem is the transmission of the generated electricity to its consumers in the most efficient fashion. High transmission and Distribution losses, Energy theft, peak power shortages leading to power outages are some of the real challenges a large portion of the world is facing.Ecolibrium Energy is transforming the way the world uses energy. We help commercial, institutional and industrial organizations use energy more intelligently, pay less for it, and generate cash flow that benefits the bottom line. Our technology-enabled solutions help meet the needs of utilities/grid operators that deliver energy and are responsible for maintaining the real-time balance between supply and demand.We are focusing on Energy Management Solution, Demand Response Programs for Distribution companies and renewable energy integration in the grid | $5M | Seed | Jun 13, 2022 |  |
| mPharma | mPharma offers solutions to health insurance and pharmaceutical companies to make it easier for patients to afford their medications. It aims to increase patient access to high-quality medications. mPharma partners with drug manufacturers, insurance companies, financial institutions, and governments to deliver prescription drugs directly toconsumers in emerging markets. They provide doctors, patients, and pharmacists access to a network of high-quality chronic disease medicine at sustainable prices.The company was founded by Gregory Rockson (CEO), Daniel Shoukimas (CPO), and James Finucane (CTO) in 2013. | $30M | Series D | Jan 05, 2022 |  |
| mPharma | mPharma offers solutions to health insurance and pharmaceutical companies to make it easier for patients to afford their medications. It aims to increase patient access to high-quality medications. mPharma partners with drug manufacturers, insurance companies, financial institutions, and governments to deliver prescription drugs directly toconsumers in emerging markets. They provide doctors, patients, and pharmacists access to a network of high-quality chronic disease medicine at sustainable prices.The company was founded by Gregory Rockson (CEO), Daniel Shoukimas (CPO), and James Finucane (CTO) in 2013. | $30M |  | Jan 05, 2022 |  |
| Syfe | Syfe is an investment and saving platform empowering people to build their wealth. Syfe offers fully managed portfolios, cash management solutions, and self-directed offerings through its unique neo-brokerage, making it the region’s only all-in-one wealth management platform. Syfe is fully licensed and operational for fund management, financialadvisory, and brokerage in Singapore, Hong Kong & Australia. The company has raised US$ 52.4m to date from prominent backers such as Valar Ventures (Transferwise, N26, Qonto), Unbound Capital (Forto, Cars24), and Partners from DST (Robinhood, Revolut, Brex, Coinbase). | $29.5M | Series B | Jul 13, 2021 |  |
| VAHA | At VAHA they are passionate about motivating people to reach their full potential and believe that everyone can live a full and energetic life through the experience of FLOW. Flow is the "sweet spot" where the challenge fits your personal skills perfectly. This is exactly the point at which optimal progress and absolute motivation areachieved. |  | Series B | Nov 26, 2020 |  |
| Syfe | Syfe is an investment and saving platform empowering people to build their wealth. Syfe offers fully managed portfolios, cash management solutions, and self-directed offerings through its unique neo-brokerage, making it the region’s only all-in-one wealth management platform. Syfe is fully licensed and operational for fund management, financialadvisory, and brokerage in Singapore, Hong Kong & Australia. The company has raised US$ 52.4m to date from prominent backers such as Valar Ventures (Transferwise, N26, Qonto), Unbound Capital (Forto, Cars24), and Partners from DST (Robinhood, Revolut, Brex, Coinbase). | $18.6M | Series A | Sep 23, 2020 |  |

10 of 19 investments shown.

## Co-investors
- [Golden Palm Investments](https://shizune.co/investors/profile/golden-palm-investments) — VC Fund, 4 deals together
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 4 deals together
- [Valar Ventures](https://shizune.co/investors/profile/valar-ventures) — VC Fund, 4 deals together
- [DST Global](https://shizune.co/investors/profile/digital-sky-technologies-fo) — VC Fund, 3 deals together
- [Exor Ventures](https://shizune.co/investors/profile/exor-seeds) — VC Fund, 3 deals together
- [Moore Strategic Ventures](https://shizune.co/investors/profile/moore-strategic-ventures) — VC Fund, 3 deals together

## About Unbound

VC Fund · London, United Kingdom

Unbound is building and backing the next generation of 100-year companies. We invest in fast growing technology companies operating in the growth stage (Series B onwards). The firm invests globally across both developed and emerging markets.

4 contacts available at Unbound.

| Name | Title | Profile |
| --- | --- | --- |
| Rohit Krishnan | Director | https://shizune.co/investors/profile/rohit-krishnan |
| Shravin Bharti Mittal | Co-Founder | https://shizune.co/investors/profile/shravin-bharti-mittal |
| Tian Tian Feng | Growth Investor | https://shizune.co/investors/profile/tian-tian-feng |
| Vikram Dhingra | CEO | https://shizune.co/investors/profile/vikram-dhingra-62d7 |

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Golden Palm Investments](https://shizune.co/investors/profile/golden-palm-investments) — VC Fund
- [Good Soil VC](https://shizune.co/investors/profile/good-soil-vc) — VC Fund
- [Launch Africa](https://shizune.co/investors/profile/launch-africa) — VC Fund

## Featured in investor lists
- [All Angel Investors in Ghana](https://shizune.co/investors/angel-investors-ghana)
- [Health Care Investors in Ghana](https://shizune.co/investors/health-care-investors-ghana)
- [All Investors in Ghana](https://shizune.co/investors/investors-ghana)
- [Health Care Angel Investors in Ghana](https://shizune.co/investors/health-care-angel-investors-ghana)

## FAQ

### What does Shravin Bharti Mittal invest in?

Shravin Bharti Mittal invests primarily in Health Care, FinTech and Fitness startups, most often at Series B and Seed stage. Most of the 19 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Shravin Bharti Mittal's check size?

Shravin Bharti Mittal typically joins rounds of $4M–$5M at Seed, $6.6M–$19M at Series A and $9.7M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shravin Bharti Mittal participates in.

### When did Shravin Bharti Mittal last invest?

The most recent investment recorded for Shravin Bharti Mittal closed in Jun 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co